TCGA-E9-A3QA-01A-61R-A22K-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 31
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.650
- INTERFERON_ALPHA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.620
- INFLAMMATORY_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.540
- MYC_TARGETS_V2+0.520
- TNFA_SIGNALING_VIA_NFKB+0.480
- E2F_TARGETS+0.370
- COMPLEMENT+0.360
- IL2_STAT5_SIGNALING+0.350
Top 10 suppressed
- PROTEIN_SECRETION-0.420
- ESTROGEN_RESPONSE_EARLY-0.310
- UV_RESPONSE_DN-0.300
- OXIDATIVE_PHOSPHORYLATION-0.270
- TGF_BETA_SIGNALING-0.270
- ANDROGEN_RESPONSE-0.240
- FATTY_ACID_METABOLISM-0.230
- PEROXISOME-0.180
- PANCREAS_BETA_CELLS-0.160
- ADIPOGENESIS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.903 |
| 2 | TCGA-A7-A6VY-01A-12R-A33J-07 | — | E | 0.886 |
| 3 | TCGA-AO-A129-01A-21R-A10J-07 | — | E | 0.884 |
| 4 | TCGA-E2-A573-01A-11R-A29R-07 | — | E | 0.883 |
| 5 | 20050099.TNBC | — | D | 0.879 |
| 6 | TCGA-A8-A07U-01A-11R-A034-07 | — | D | 0.877 |
| 7 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.875 |
| 8 | BSR_16_0031_E2_S98 | — | C | 0.874 |
| 9 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.866 |
| 10 | TCGA-A2-A04Q-01A-21R-A034-07 | — | D | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.620 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |